Arkadios Wealth Advisors Grows Stake in HCA Healthcare, Inc. (NYSE:HCA)

Arkadios Wealth Advisors grew its position in HCA Healthcare, Inc. (NYSE:HCA) by 46.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,435 shares of the company’s stock after buying an additional 1,096 shares during the quarter. Arkadios Wealth Advisors’ holdings in HCA Healthcare were worth $1,031,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. FMR LLC grew its position in shares of HCA Healthcare by 322.3% in the third quarter. FMR LLC now owns 3,141,769 shares of the company’s stock valued at $1,276,909,000 after purchasing an additional 2,397,883 shares during the last quarter. Franklin Resources Inc. increased its position in HCA Healthcare by 11.7% during the third quarter. Franklin Resources Inc. now owns 1,669,721 shares of the company’s stock worth $660,842,000 after buying an additional 174,946 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of HCA Healthcare by 2.8% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,487,367 shares of the company’s stock valued at $604,511,000 after acquiring an additional 41,190 shares during the last quarter. Janus Henderson Group PLC raised its stake in HCA Healthcare by 12.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,339,638 shares of the company’s stock valued at $544,467,000 after purchasing an additional 143,995 shares during the last quarter. Finally, Darsana Capital Partners LP boosted its stake in shares of HCA Healthcare by 53.3% during the 2nd quarter. Darsana Capital Partners LP now owns 1,150,000 shares of the company’s stock worth $369,472,000 after purchasing an additional 400,000 shares during the last quarter. 62.73% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have commented on HCA. Raymond James cut shares of HCA Healthcare from an “outperform” rating to a “market perform” rating in a research note on Friday, November 22nd. Oppenheimer raised their price target on HCA Healthcare from $390.00 to $400.00 and gave the stock an “outperform” rating in a research note on Monday, October 28th. TD Cowen decreased their target price on shares of HCA Healthcare from $450.00 to $440.00 and set a “buy” rating on the stock in a research report on Monday, October 28th. Barclays decreased their price target on shares of HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. Finally, Truist Financial cut their target price on HCA Healthcare from $430.00 to $390.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $385.27.

Insiders Place Their Bets

In other HCA Healthcare news, SVP Phillip G. Billington sold 3,897 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $350.00, for a total value of $1,363,950.00. Following the sale, the senior vice president now owns 52,702 shares in the company, valued at approximately $18,445,700. This trade represents a 6.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Erol R. Akdamar sold 2,900 shares of the stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the transaction, the insider now directly owns 6,843 shares of the company’s stock, valued at $2,415,579. This trade represents a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by company insiders.

HCA Healthcare Stock Performance

Shares of HCA stock opened at $310.60 on Monday. HCA Healthcare, Inc. has a 12 month low of $278.50 and a 12 month high of $417.14. The firm has a market capitalization of $78.68 billion, a P/E ratio of 13.95, a P/E/G ratio of 1.03 and a beta of 1.64. The company has a debt-to-equity ratio of 48.71, a current ratio of 1.12 and a quick ratio of 1.00. The company’s fifty day moving average price is $316.69 and its two-hundred day moving average price is $353.01.

HCA Healthcare Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, December 27th. Investors of record on Friday, December 13th were paid a $0.66 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $2.64 dividend on an annualized basis and a yield of 0.85%. HCA Healthcare’s dividend payout ratio (DPR) is 11.85%.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.